UCB, Novartis ink German licensing deal

UCB is expanding in Germany with a new Novartis licensing agreement for cardiovascular and diabetes products. UCB gains extended commercial rights to the cardio drug medication Provas beyond 2011. The Belgian drugmaker also gets commercial rights for two line extensions: the hypertension drugs Dafiro and Dafiro HCT. Finally, UCB and Novartis will co-commercialize the two new oral anti-diabetics, Jalra and Icandra.

A spokesperson for the company said the deal helps UBC build its business in Germany, which is UCB's second-largest market. UCB Germany, which focuses on the fields of central nervous system, immunology disorders and internal medicine, employs about 1,400 people. Financial details of the deal were not disclosed.

- see UCB's release
- read the article from Reuters

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.